

Member FINRA/SIPC

Toll-Free: 561-391-5555 ♦ www.DawsonJames.com ♦ 101 North Federal Highway - Suite 600 ♦ Boca Raton, FL 33432

Citius Pharmaceuticals (NASDAQ/CTXR)

January 26, 2021

BUY: Builds Cash Runway to Commercialization

Citius raises cash - approximately \$20.0 million, through the issuance of 15M shares and warrants to purchase another 7.7M shares at a purchase price of \$1.294 per share (at-the-market). Closing is expected to occur on or about January 27, 2021. We applaud the move as the company now should have enough capital to commercialize Mino-Lok. Our model assumes dilution, so this raise has only a slight impact on our valuation with our price target adjusting from \$7.00 to \$6.00 due to rounding.

Jason Kolbert
 Healthcare Research
 jkolbert@dawsonjames.com

Investment Highlights

What is Mino-Lok? Three active drug substances (minocycline, ethanol, and EDTA), which are combined into two vials, MLT01 (minocycline) and MLT02 (ethanol and EDTA). Citius has manufactured three registration lots of Mino-Lok using the commercial manufacturing process, part of the planned New Drug Application (NDA). Citius has placed all registration lots on stability at the appropriate ICH (The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) conditions to support the NDA filing. Citius has also developed a new exclusive synthesis process for disodium edetate, a chelating agent that supplants heparin as the anti-clotting agent in Mino-Lok.

Trial Background. The current Phase 3 trial being conducted compares Mino-Lok therapy (MLT) to the standard of care, which is antibiotic lock therapy (ALT). This is used to disinfect colonized catheters causing bacteremia and keep the treated catheters functioning and infection-free for eight weeks post-therapy. The current primary endpoint in the study is planned to demonstrate a significant difference in the time to catheter failure when comparing MLT to ALT. This is clinically important because eliminating the source of infection enables antibiotic treatment of the bacteremia to work more effectively and expeditiously. Additionally, if a catheter can be maintained for the time that it is needed, the patient does not need to be subjected to the procedures for removing and replacing the catheters that are associated with some serious adverse events.

DMC Said Keep Going as Planned. This past September, the DMC recommended continuing the trial without any modifications. The DMC further requested to have an ad hoc meeting in the near future. Recall that the trial (Sept. 2019) reached the first interim analysis point of 37 catheter failures representing 40% of the anticipated events at ~58 patients. Recall that the trial is designed with 80% power for an assumed 17-day difference between active and standard of care (SOC). We typically expect the SOC arm to fail in 5-14 days.

Valuation. Please see our complete valuation metrics (next page).

Risk Factors: These include Clinical Risk, Partnership Risk, Investment and Financial Risk, Regulatory Risk, Market Share Risk, and Legal and Commercial Risks.

Current Price	\$1.00
Price Target	\$ 6.00

Estimates	F2020E	F2021E	F2022E
Expenses (\$000s)	\$ 18,525	\$ 31,190	\$ 49,107
1Q December	\$ 4,448	\$ 7,352	\$ 11,777
2Q March	\$ 4,433	\$ 7,575	\$ 12,027
3Q June	\$ 4,689	\$ 7,797	\$ 12,277
4Q September	\$ 4,955	\$ 8,465	\$ 13,026
	F2020E	F2021E	F2022E
EPS	\$ (0.49)	\$ 0.68	\$ 1.45
1Q December	\$ (0.15)	\$ 0.16	\$ 0.33
2Q March	\$ (0.13)	\$ 0.16	\$ 0.35
3Q June	\$ (0.11)	\$ 0.17	\$ 0.36
4Q September	\$ (0.11)	\$ 0.19	\$ 0.41

EBITDA/Share	
EV/EBITDA (x)	
Stock Data	
52-Week Range	\$0.40 - \$1.97
Shares Outstanding (mil.)	55.5
Market Capitalization (mil.)	\$55
Enterprise Value (mil.)	\$36
Debt to Capital	0%
Book Value/Share	\$2.63
Price/Book	0.9
Average Three Months Trading Volume (K)	10,578
Insider Ownership	25.0%
Institutional Ownership	1.7%
Short Interest (mil.)	1.3%
Dividend / Yield	\$0.00/0.0%



Valuation. Our valuation is based on our therapeutic models and associated assumptions projected to 2028. Our model assumes multiple financial raises, and as such, our share count is based on a fully diluted out year basis. The lead product, Mini-Lok, is now in a Phase 3 trial. We conservatively assume just 50% probability of success in our models. On top of this, we also use a 30% risk rate in our free cash flow to the firm (FCFF), our discounted EPS (dEPS) and sum-of-the-parts (SOP) models. We equal weight and average these metrics and then round to the nearest whole number to derive our \$6.00 price target.

Exhibit 1. FCFF Model

Average of Metrics & Rounded \$		6.00
Price Target \$	6.00	
Year	2021	

DCF Valuation Using FCF (min):

units ('000 - Cnd\$)	2019E	2020E	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E
EBIT (Earnings before income tax)	(15,560)	(18,525)	50,452	117,459	155,929	195,898	237,411	280,513	325,253	371,677
Tax Rate	0%	0%	5%	10%	15%	20%	25%	30%	35%	38%
EBIT(1-t) Earnings after income tax	(15,560)	(18,525)	47,930	105,713	132,540	156,718	178,058	196,359	211,414	230,440
CapEx (equipment)	-	(2)	-	-	-	-	-	-	-	-
Depreciation	-	429	-	-	-	-	-	-	-	-
Change in NWC	-	-	-	-	-	-	-	-	-	-
FCF	(15,560)	(18,098)	47,930	105,713	132,540	156,718	178,058	196,359	211,414	230,440
PV of FCF	(26,296)	(23,527)	47,930	81,318	78,426	71,333	62,343	52,885	43,800	36,724
Discount Rate	30%									
Long Term Growth Rate	1%									
Terminal Cash Flow	802,566									
Terminal Value YE2023	127,902									
NPV	552,837									
NPV-Debt	-									
Shares out ('000)	87,411	2028E								
NPV Per Share	\$ 6.32									

Source: Dawson James estimates

Exhibit 2. Discounted EPS Model

Current Year	2021
Year of EPS	2028
Earnings Multiple	15
Discount Factor	30%
Selected Year EPS	\$ 2.63
NPV	\$ 6.30

Discount Rate and Earnings Multiple Varies, Year is Constant								
		2028 EPS						
		6.30	5%	10%	15%	20%	25%	30%
Earnings Multiple	5	\$9.36	\$6.76	\$4.95	\$3.68	\$2.76	\$ 2.10	
	10	\$18.72	\$13.52	\$9.90	\$7.35	\$5.52	\$ 4.20	
	15	\$28.08	\$20.28	\$14.86	\$11.03	\$8.29	\$ 6.30	
	20	\$37.44	\$27.04	\$19.81	\$14.70	\$11.05	\$ 8.40	
	25	\$46.80	\$33.80	\$24.76	\$18.38	\$13.81	\$ 10.50	
	30	\$56.17	\$40.56	\$29.71	\$22.06	\$16.57	\$ 12.59	
	35	\$65.53	\$47.31	\$34.66	\$25.73	\$19.34	\$ 14.69	
	40	\$74.89	\$54.07	\$39.61	\$29.41	\$22.10	\$ 16.79	

Source: Dawson James estimates

Exhibit 3. Sum of the Parts Model

	LT Gr	Discount Rate	Yrs. to Peak	% Success	Peak Sales MMs	Term Val
MiniLok LT & ST CVC U.S.	1%	30%	3	70%	\$469	\$1,618
						\$4.13
MiniLok LT & ST CVC E.U.	1%	30%	6	80%	\$0	\$0
						\$0.00
MiniLok LT & ST CVC China	1%	30%	7	80%	\$0	\$0
						\$0.00
Hydro-Lido	1%	30%	5	0%	\$0	\$0
Pre-Clinical Pipeline						\$0.00
Net Margin						70%
MM Shrs OS						87
Total						\$4.13

Source: Dawson James estimates

Exhibit 4. Income Statement

Citius Pharmaceuticals: Income Statement (\$000)																		
YE Sept.	2019A	1Q20A	2Q20A	3Q20A	4Q20E	2020E	December	March	June	Sept. YE								
							1Q21E	2Q21E	3Q21E	4Q21E	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E
Mno-Lok, U.S. ST & LT CVC Revenues	-	-	-	-	-	-	18,778	19,594	20,410	22,860	81,642	166,566	212,392	259,994	309,423	360,734	413,983	469,227
Mno-Lok, E.U. ST & LT CVC Revenues	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Mno-Lok, CHina ST & LT CVC Revenues	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	-	18,778	19,594	20,410	22,860	81,642	166,566	212,392	259,994	309,423	360,734	413,983	469,227
Expenses																		
Cost of goods sold	-	-	-	-	-	-	2,817	2,939	3,062	3,429	12,246	24,985	31,859	38,999	46,413	54,110	62,097	70,384
COGS % of Revenue		15%	15%	15%	15%		15%	15%	15%	15%	15%	15%	15%	15%	15%	15%	15%	15%
Research and development	8,596	2,665	2,016	2,644	2,455	8,768	2,236	2,236	2,236	2,236	8,943	9,122	9,305	9,491	9,680	9,874	10,072	10,273
R&D % of Revenue																		
G&A	6,285	1,563	2,258	1,870	2,500	8,191	2,300	2,400	2,500	2,800	10,000	15,000	15,300	15,606	15,918	16,236	16,561	16,892
SG&A % of Revenue																		
Stock based comp. G & A	715	220	159	175		554												
Total expenses	15,596	4,448	4,433	4,689	4,955	18,525	7,352	7,575	7,797	8,465	31,190	49,107	56,463	64,096	72,012	80,221	88,730	97,549
Oper. Inc. (Loss)	(15,596)	(4,448)	(4,433)	(4,689)	(4,955)	(18,525)	11,425	12,019	12,613	14,395	50,452	117,459	155,929	195,898	237,411	280,513	325,253	371,677
Interest Income	53	110	12	13														
Gain (loss) on revaluation of derivative warrant liability		19																
Interest Expense	(16)	(4)	(4)	(4)														
Pre-tax income	(15,560)	(4,323)	(4,425)	(4,680)	(4,955)	(18,525)	11,425	12,019	12,613	14,395	50,452	117,459	155,929	195,898	237,411	280,513	325,253	371,677
Income Tax Benefit (Provision)	-	-	-	-	-	-	571	601	631	720	2,523	11,746	23,389	39,180	59,353	84,154	113,838	141,237
Tax Rate	0%	0%	0%	0%	0%	0%	5%	5%	5%	5%	5%	10%	15%	20%	25%	30%	35%	38%
GAAP Net Income (loss)	(15,560)	(4,323)	(4,425)	(4,680)	(4,955)	(18,383)	10,854	11,418	11,982	13,675	47,930	105,713	132,540	156,718	178,058	196,359	211,414	230,440
GAAP-EPS	(0.53)	(0.15)	(0.13)	(0.11)	(0.11)	(0.49)	0.16	0.16	0.17	0.19	0.68	1.45	1.76	2.02	2.23	2.38	2.49	2.63
Non GAAP EPS (dil)	(0.61)	(0.11)	(0.13)	(0.11)	(0.11)	(0.46)	0.16	0.16	0.17	0.19	0.68	1.45	1.76	2.02	2.23	2.38	2.49	2.63
Wgtd Avg Shrs (Bas) - '000s	20,162	29,197	34,319	41,600	46,642	37,940	62,145	62,207	62,269	62,331	62,238	62,487	62,738	62,989	63,241	63,495	63,749	64,004
Wgtd Avg Shrs (Dil) - '000s	35,000	39,197	34,319	41,600	47,016	40,533	69,873	70,571	71,277	71,990	70,928	73,077	75,291	77,573	79,923	82,345	84,840	87,411

Source: Dawson James, company reports

Risk Analysis

In addition to the typical risks associated with development stage specialty pharmaceutical companies, potential risks specific to Citius Pharmaceuticals, Inc. are as follows:

Partnership risk. Citius Pharmaceuticals, Inc. is in discussions with possible partners today, but there can be no assurances that the company will be able to secure a favorable partnership.

Commercial risk. There are no assurances that the company will be able to achieve significant market share and become profitable.

Clinical and regulatory risk. Lead products have to complete clinical trials. Trials may not produce results sufficient for regulatory approval.

Financial risk. The company may need to raise capital in the marketplace, and there can be no assurances that the company will be able to successfully raise capital and or do so at favorable terms.


Liquidity Risk. The stock is thinly traded. We note that management owns a significant percentage of the company.

Legal and intellectual property risk. The company may have to defend its patents and technical know-how, and there can be no assurances that the patents will not be infringed or will be held as valid if challenged, and or that the company may infringe on third parties' patents.

Companies mentioned in this report

Important Disclosures:

Price Chart:



Price target and rating changes over the past three years:

- Initiation – Buy – 12/15/2017 – Price Target \$10.00
- Update – Buy – 7/6/2018 – Price Target \$10.00
- Transfer – Buy – 9/6/2019 – Price Target \$7.00
- Update – Buy – 10/7/2019 – Price Target \$7.00
- Update – Buy – 12/19/2019 – Price Target \$7.00
- Update – Buy – 2/4/2020 – Price Target \$7.00
- Update – Buy – 2/25/2020 – Price Target \$7.00
- Update – Buy – 5/26/2020 – Price Target \$7.00
- Update – Buy – 9/28/2020 – Price Target \$7.00
- Update – Buy – 9/29/2020 – Price Target \$7.00
- Update – Buy – 11/30/2020 – Price Target \$7.00
- Update – Buy – 1/26/2021 – Price Target \$6.00

Dawson James Securities, Inc. (the “Firm”) is a member of the Financial Industry Regulatory Authority (“FINRA”) and the Securities Investor Protection Corporation (“SIPC”).

The Firm does not make a market in the securities of the subject company(s). The Firm has NOT engaged in investment banking relationships with the subject company in the prior twelve months, as a manager or co-manager of a public offering and has NOT received compensation resulting from those relationships. The Firm may seek compensation for investment banking services in the future from the subject company(s). The Firm has received other compensation from the subject company(s) in the last 12 months for services unrelated to managing or co-managing of a public offering.

Neither the research analyst(s) whose name appears on this report nor any member of his (their) household is an officer, director or advisory board member of these companies. The Firm and/or its directors and employees may own securities of the company(s) in this report and may increase or decrease holdings in the future. As of December 31, 2020, the Firm as a whole did not beneficially own 1% or more of any class of common equity securities of the subject company(s) of this report. The Firm, its officers, directors, analysts or employees may affect transactions in and have long or short positions in the securities (or options or warrants related to those securities) of the company(s) subject to this report. The Firm may affect transactions as principal or agent in those securities.

Analysts receive no direct compensation in connection with the Firm's investment banking business. All Firm employees, including the analyst(s) responsible for preparing this report, may be eligible to receive non-product or service-specific monetary bonus compensation that is based upon various factors, including total revenues of the Firm and its affiliates as well as a portion of the proceeds from a broad

pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.

Although the statements in this report have been obtained from and are based upon recognized statistical services, issuer reports or communications, or other sources that the Firm believes to be reliable, we cannot guarantee their accuracy. All opinions and estimates included in this report constitute the analyst's judgment as of the date of this report and are subject to change without notice.

Information about valuation methods and risks can be found in the "VALUATION" and "RISK ANALYSIS" sections of this report.

The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. This report is offered for informational purposes only and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. Additional information is available upon request.

Rating Definitions:

- 1) **Buy:** The analyst believes the price of the stock will appreciate and produce a total return of at least 20% over the next 12-18 months;
- 2) **Neutral:** The analyst believes the price of the stock is fairly valued for the next 12-18 months;
- 3) **Sell:** The analyst believes the price of the stock will decline by at least 20% over the next 12-18 months and should be sold.

The following chart reflects the range of current research report ratings for all companies followed by the analysts of the Firm. The chart also reflects the research report ratings relating to those companies for which the Firm has performed investment banking services.

Ratings Distribution	Company Coverage		Investment Banking	
	# of Companies	% of Total	# of Companies	% of Totals
Market Outperform (Buy)	22	79%	2	9%
Market Perform (Neutral)	6	21%	0	0%
Market Underperform (Sell)	0	0%	0	0%
Total	28	100%	2	7%

Analyst Certification:

The analyst(s) whose name appears on this research report certifies that 1) all of the views expressed in this report accurately reflect his (their) personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst in this research report; and 3) all Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service-specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.